Literature DB >> 22410852

Osteopontin biomarker in inflammatory bowel disease, animal models and target for drug discovery.

Manuela G Neuman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22410852     DOI: 10.1007/s10620-012-2120-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  24 in total

1.  Expression of osteopontin (Eta-1) in Crohn disease of the terminal ileum.

Authors:  N Gassler; F Autschbach; S Gauer; J Bohn; B Sido; H F Otto; H Geiger; N Obermüller
Journal:  Scand J Gastroenterol       Date:  2002-11       Impact factor: 2.423

2.  Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling.

Authors:  Marie-Alice Meuwis; Marianne Fillet; Pierre Geurts; Dominique de Seny; Laurence Lutteri; Jean-Paul Chapelle; Vincent Bours; Louis Wehenkel; Jacques Belaiche; Michel Malaise; Edouard Louis; Marie-Paule Merville
Journal:  Biochem Pharmacol       Date:  2006-12-20       Impact factor: 5.858

3.  High plasma osteopontin levels in patients with inflammatory bowel disease.

Authors:  Ryosuke Mishima; Fuminao Takeshima; Terumitsu Sawai; Kazuo Ohba; Ken Ohnita; Hajime Isomoto; Katsuhisa Omagari; Yohei Mizuta; Yoshiyuki Ozono; Shigeru Kohno
Journal:  J Clin Gastroenterol       Date:  2007-02       Impact factor: 3.062

4.  Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue.

Authors:  M Briskin; D Winsor-Hines; A Shyjan; N Cochran; S Bloom; J Wilson; L M McEvoy; E C Butcher; N Kassam; C R Mackay; W Newman; D J Ringler
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

5.  Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7.

Authors:  P E Hesterberg; D Winsor-Hines; M J Briskin; D Soler-Ferran; C Merrill; C R Mackay; W Newman; D J Ringler
Journal:  Gastroenterology       Date:  1996-11       Impact factor: 22.682

6.  Osteopontin expression in ulcerative colitis is distinctly different from that in Crohn's disease and diverticulitis.

Authors:  Hideki Masuda; Yasuo Takahashi; Satoshi Asai; Akihiro Hemmi; Tadatoshi Takayama
Journal:  J Gastroenterol       Date:  2005-04       Impact factor: 7.527

7.  A humanized anti-osteopontin antibody protects from Concanavalin A induced-liver injury in mice.

Authors:  Kexing Fan; Bo Zhang; Haiou Yang; Huajing Wang; Min Tan; Sheng Hou; Weizhu Qian; Bohua Li; Hao Wang; Jianxin Dai; Yajun Guo
Journal:  Eur J Pharmacol       Date:  2011-02-25       Impact factor: 4.432

8.  Osteopontin ablation attenuates progression of colitis in TNBS model.

Authors:  Helieh S Oz; Jian Zhong; Willem J S de Villiers
Journal:  Dig Dis Sci       Date:  2011-12-16       Impact factor: 3.199

9.  Adhesion molecules in inflammatory bowel disease.

Authors:  S C Jones; R E Banks; A Haidar; A J Gearing; I K Hemingway; S H Ibbotson; M F Dixon; A T Axon
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

Review 10.  Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science.

Authors:  Florian Rieder; Claudio Fiocchi
Journal:  Curr Opin Gastroenterol       Date:  2008-07       Impact factor: 3.287

View more
  2 in total

1.  Smooth muscle-specific MMP17 (MT4-MMP) regulates the intestinal stem cell niche and regeneration after damage.

Authors:  Mara Martín-Alonso; Sharif Iqbal; Pia M Vornewald; Håvard T Lindholm; Mirjam J Damen; Fernando Martínez; Sigrid Hoel; Alberto Díez-Sánchez; Maarten Altelaar; Pekka Katajisto; Alicia G Arroyo; Menno J Oudhoff
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

2.  Osteopontin expression by CD103- dendritic cells drives intestinal inflammation.

Authors:  Evangelia Kourepini; Maria Aggelakopoulou; Themis Alissafi; Nikolaos Paschalidis; Davina C M Simoes; Vily Panoutsakopoulou
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.